NASDAQ:JYNT

The Joint Stock Forecast, Price & News

$29.93

+0.11 (+0.37 %)

(As of 01/25/2021 12:00 AM ET)

Add

Compare

Today's Range

$29.14

Now: $29.93▼

$30.48

50-Day Range

$25.54

MA: $27.32▼

$29.82

52-Week Range

$7.67

Now: $29.93▼

$30.48

Volume69,900 shs

Average Volume93,133 shs

Market Capitalization$420.25 million

P/E Ratio110.86

Dividend YieldN/A

Beta1.27

The Joint Corp. develops, owns, operates, supports, and manages chiropractic clinics in the United States. The company operates through two segments, Corporate Clinics and Franchise Operations. It operates through direct ownership, management arrangements, franchising and the sale of regional developer rights. As of December 31, 2019, the company operated approximately 513 clinics in the United States. The company was founded in 2010 and is headquartered in Scottsdale, Arizona.

MarketRank^™

Overall MarketRank^™

1.26 out of 5 stars

Medical Sector

744th out of 1,922 stocks

Patent Owners & Lessors Industry

8th out of 28 stocks

1.5 Analyst's Opinion

Consensus Rating
The Joint has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $31.60, The Joint has a forecasted upside of 5.6% from its current price of $29.93.
Amount of Analyst Coverage
The Joint has only been the subject of 3 research reports in the past 90 days.

2.5 Community Rank

Outperform Votes
The Joint has received 251 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
The Joint has received 245 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
The Joint has received 50.60% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about The Joint and other stocks. Vote “Outperform” if you believe JYNT will outperform the S&P 500 over the long term. Vote “Underperform” if you believe JYNT will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
The Joint does not currently pay a dividend.
Dividend Growth
The Joint does not have a long track record of dividend growth.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, The Joint insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 6.10% of the stock of The Joint is held by insiders.
Percentage Held by Institutions
73.05% of the stock of The Joint is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for The Joint are expected to grow by 3.23% in the coming year, from $0.31 to $0.32 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of The Joint is 110.86, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 24.44.
Price to Earnings Ratio vs. Sector
The P/E ratio of The Joint is 110.86, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 36.63.
Price to Book Value per Share Ratio
The Joint has a P/B Ratio of 73.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Patent owners & lessors

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:JYNT

Previous Symbol

CUSIPN/A

CIK1612630

Webwww.thejoint.com

Phone480-245-5960

Employees150

Year FoundedN/A

Debt

Debt-to-Equity Ratio0.34

Current Ratio1.38

Quick Ratio1.38

Price-To-Earnings

Trailing P/E Ratio110.86

Forward P/E Ratio96.55

P/E GrowthN/A

Sales & Book Value

Annual Sales$48.45 million

Price / Sales8.67

Cash Flow$0.39 per share

Price / Cash Flow75.94

Book Value$0.41 per share

Price / Book73.00

Profitability

EPS (Most Recent Fiscal Year)$0.23

Net Income$3.32 million

Net Margins6.89%

Return on Equity51.77%

Return on Assets7.98%

Miscellaneous

Outstanding Shares14,041,000

Market Cap$420.25 million

Next Earnings Date3/4/2021 (Estimated)

OptionableNot Optionable

$29.93

+0.11 (+0.37 %)

(As of 01/25/2021 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive JYNT News and Ratings via Email

Sign-up to receive the latest news and ratings for JYNT and its competitors with MarketBeat's FREE daily newsletter.

The Joint (NASDAQ:JYNT) Frequently Asked Questions

How has The Joint's stock been impacted by COVID-19 (Coronavirus)?

The Joint's stock was trading at $13.61 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, JYNT stock has increased by 119.9% and is now trading at $29.93.
View which stocks have been most impacted by COVID-19.

Is The Joint a buy right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for The Joint in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" The Joint stock.
View analyst ratings for The Joint or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than The Joint?

Wall Street analysts have given The Joint a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but The Joint wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Peter D. Holt's approval rating as The Joint's CEO?

87 employees have rated The Joint CEO Peter D. Holt on Glassdoor.com. Peter D. Holt has an approval rating of 59% among The Joint's employees. This puts Peter D. Holt in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

When is The Joint's next earnings date?

The Joint is scheduled to release its next quarterly earnings announcement on Thursday, March 4th 2021.
View our earnings forecast for The Joint.

How were The Joint's earnings last quarter?

The Joint Corp. (NASDAQ:JYNT) posted its quarterly earnings data on Thursday, November, 5th. The company reported $0.11 EPS for the quarter, topping the Zacks' consensus estimate of $0.03 by $0.08. The company earned $15.41 million during the quarter, compared to analyst estimates of $13.57 million. The Joint had a net margin of 6.89% and a trailing twelve-month return on equity of 51.77%.
View The Joint's earnings history.

What guidance has The Joint issued on next quarter's earnings?

The Joint updated its FY 2020 After-Hours earnings guidance on Thursday, November, 5th. The company provided EPS guidance of for the period. The company issued revenue guidance of $58-59 million, compared to the consensus revenue estimate of $54.87 million.

What price target have analysts set for JYNT?

5 analysts have issued 1-year target prices for The Joint's shares. Their forecasts range from $26.00 to $38.00. On average, they anticipate The Joint's share price to reach $31.60 in the next twelve months. This suggests a possible upside of 5.6% from the stock's current price.
View analysts' price targets for The Joint or view Wall Street analyst' top-rated stocks.

Who are some of The Joint's key competitors?

Some companies that are related to The Joint include Franchise Group (FRG), Marathon Patent Group (MARA), Liberty Tax (TAXA), VirnetX (VHC), Acacia Research (ACTG), Quarterhill (QTRHF), Research Frontiers (REFR), Pendrell (PCOA), Network-1 Technologies (NTIP), MGT Capital Investments (MGTI), Xcel Brands (XELB), Health Discovery (HDVY), Mills Music Trust (MMTRS), Micro Imaging Technology (MMTC) and ARC Group (RLLY).
View all of JYNT's competitors.

What other stocks do shareholders of The Joint own?

Based on aggregate information from My MarketBeat watchlists, some companies that other The Joint investors own include Aurora Cannabis (ACB), Advanced Micro Devices (AMD), Raytheon Technologies (RTX), salesforce.com (CRM), Mastercard (MA), Starbucks (SBUX), Twitter (TWTR), Viking Therapeutics (VKTX), AbbVie (ABBV) and Adobe (ADBE).

Who are The Joint's key executives?

The Joint's management team includes the following people:

Mr. Peter D. Holt, CEO, Pres & Director (Age 61, Pay $666.57k)
Jake Singleton, Chief Financial Officer (Age 38, Pay $303.41k)
Mr. Jorge Armenteros, VP of Operations
Dr. Steven Knauf, Director of Chiropractic & Compliance
Mr. Jason Greenwood, VP of Marketing
Ms. Amy Karroum, VP of HR
Mr. Craig P. Colmar, Sec. (Age 67)
Mr. Eric Simon, VP of Franchise Sales & Devel.
Mr. David Glover, Regional Developer for West Lake Hills
Mr. Richard Matthews, Director of Real Estate Research

When did The Joint IPO?

(JYNT) raised $20 million in an initial public offering (IPO) on Tuesday, November 11th 2014. The company issued 3,000,000 shares at a price of $6.50 per share. Roth Capital Partners and Feltl and Company served as the underwriters for the IPO and Sanders Morris Harris was co-manager.

What is The Joint's stock symbol?

The Joint trades on the NASDAQ under the ticker symbol "JYNT."

Who are The Joint's major shareholders?

The Joint's stock is owned by a variety of institutional and retail investors. Top institutional investors include Mesirow Financial Investment Management Inc. (0.15%). Company insiders that own The Joint stock include Bandera Partners Llc, Glenn J Krevlin, Jake Singleton, James H Amos Jr, Peter D Holt and Ronald V Davella.
View institutional ownership trends for The Joint.

Which institutional investors are selling The Joint stock?

JYNT stock was sold by a variety of institutional investors in the last quarter, including Mesirow Financial Investment Management Inc..
View insider buying and selling activity for The Joint or view top insider-selling stocks.

How do I buy shares of The Joint?

Shares of JYNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is The Joint's stock price today?

One share of JYNT stock can currently be purchased for approximately $29.93.

How big of a company is The Joint?

The Joint has a market capitalization of $420.25 million and generates $48.45 million in revenue each year. The company earns $3.32 million in net income (profit) each year or $0.23 on an earnings per share basis. The Joint employs 150 workers across the globe.

What is The Joint's official website?

The official website for The Joint is www.thejoint.com.

How can I contact The Joint?

The Joint's mailing address is 16767 N PERIMETER DRIVE SUITE 240, SCOTTSDALE AZ, 85260. The company can be reached via phone at 480-245-5960 or via email at [email protected]

This page was last updated on 1/26/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here